Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Two Formulations of Gecacitinib Hydrochloride Tablets in Healthy Adults
NCT07565597Phase 1Active, not recruiting
- Sponsor
- Zelgen
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of jaktinib (2 arms), sponsored by Zelgen. Primary endpoints: Maximum Plasma Concentration up to 48 hours, Area Under the Curve from time zero to last quantifiable concentration up to 48 hours and 1 more. Started May 2026; status: active, not recruiting.
02
Drugs
jaktinib
Beyond the preview
Go deeper on NCT07565597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565597.